It is also possible to detect potentially actionable activating genetic abnormalities specific to primary tumours (e.g., EGFR gene mutations or ALK and ROS1 gene rearrangements in patients with NSCLC) [52,54,64]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.